PortalPublikationenEuroGuiDerm Guideline on the systemic treatment of Psoriasis...

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations

Standard

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. / Nast, A; Smith, C; Spuls, P I; Avila Valle, G; Bata-Csörgö, Z; Boonen, H; De Jong, E; Garcia-Doval, I; Gisondi, P; Kaur-Knudsen, D; Mahil, S; Mälkönen, T; Maul, J T; Mburu, S; Mrowietz, U; Reich, K; Remenyik, E; Rønholt, K M; Sator, P G; Schmitt-Egenolf, M; Sikora, M; Strömer, K; Sundnes, O; Trigos, D; Van Der Kraaij, G; Yawalkar, N; Dressler, C.

in: J EUR ACAD DERMATOL, Jahrgang 34, Nr. 11, 11.2020, S. 2461-2498.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung

Harvard

Nast, A, Smith, C, Spuls, PI, Avila Valle, G, Bata-Csörgö, Z, Boonen, H, De Jong, E, Garcia-Doval, I, Gisondi, P, Kaur-Knudsen, D, Mahil, S, Mälkönen, T, Maul, JT, Mburu, S, Mrowietz, U, Reich, K, Remenyik, E, Rønholt, KM, Sator, PG, Schmitt-Egenolf, M, Sikora, M, Strömer, K, Sundnes, O, Trigos, D, Van Der Kraaij, G, Yawalkar, N & Dressler, C 2020, 'EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations', J EUR ACAD DERMATOL, Jg. 34, Nr. 11, S. 2461-2498. https://doi.org/10.1111/jdv.16915

APA

Nast, A., Smith, C., Spuls, P. I., Avila Valle, G., Bata-Csörgö, Z., Boonen, H., De Jong, E., Garcia-Doval, I., Gisondi, P., Kaur-Knudsen, D., Mahil, S., Mälkönen, T., Maul, J. T., Mburu, S., Mrowietz, U., Reich, K., Remenyik, E., Rønholt, K. M., Sator, P. G., ... Dressler, C. (2020). EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J EUR ACAD DERMATOL, 34(11), 2461-2498. https://doi.org/10.1111/jdv.16915

Vancouver

Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J EUR ACAD DERMATOL. 2020 Nov;34(11):2461-2498. https://doi.org/10.1111/jdv.16915

Bibtex

@article{d3bdf087e85b4a14b1ba6f07b4785469,
title = "EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations",
abstract = "This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.",
author = "A Nast and C Smith and Spuls, {P I} and {Avila Valle}, G and Z Bata-Cs{\"o}rg{\"o} and H Boonen and {De Jong}, E and I Garcia-Doval and P Gisondi and D Kaur-Knudsen and S Mahil and T M{\"a}lk{\"o}nen and Maul, {J T} and S Mburu and U Mrowietz and K Reich and E Remenyik and R{\o}nholt, {K M} and Sator, {P G} and M Schmitt-Egenolf and M Sikora and K Str{\"o}mer and O Sundnes and D Trigos and {Van Der Kraaij}, G and N Yawalkar and C Dressler",
note = "{\textcopyright} 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.",
year = "2020",
month = nov,
doi = "10.1111/jdv.16915",
language = "English",
volume = "34",
pages = "2461--2498",
journal = "J EUR ACAD DERMATOL",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "11",

}

RIS

TY - JOUR

T1 - EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations

AU - Nast, A

AU - Smith, C

AU - Spuls, P I

AU - Avila Valle, G

AU - Bata-Csörgö, Z

AU - Boonen, H

AU - De Jong, E

AU - Garcia-Doval, I

AU - Gisondi, P

AU - Kaur-Knudsen, D

AU - Mahil, S

AU - Mälkönen, T

AU - Maul, J T

AU - Mburu, S

AU - Mrowietz, U

AU - Reich, K

AU - Remenyik, E

AU - Rønholt, K M

AU - Sator, P G

AU - Schmitt-Egenolf, M

AU - Sikora, M

AU - Strömer, K

AU - Sundnes, O

AU - Trigos, D

AU - Van Der Kraaij, G

AU - Yawalkar, N

AU - Dressler, C

N1 - © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

PY - 2020/11

Y1 - 2020/11

N2 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

AB - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The first part of the guideline includes general information on the scope and purpose, health questions covered, target users and strength/limitations of the guideline. Suggestions for disease severity grading and treatment goals are provided. It presents the general treatment recommendations as well as detailed management and monitoring recommendations for the individual drugs. The treatment options discussed in this guideline are as follows: acitretin, ciclosporin, fumarates, methotrexate, adalimumab, apremilast, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab.

U2 - 10.1111/jdv.16915

DO - 10.1111/jdv.16915

M3 - Other (editorial matter etc.)

C2 - 33349983

VL - 34

SP - 2461

EP - 2498

JO - J EUR ACAD DERMATOL

JF - J EUR ACAD DERMATOL

SN - 0926-9959

IS - 11

ER -